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Puppression of Endothelial
rogenitor Cells in Human Coronary
rtery Disease by the Endogenous Nitric Oxide
ynthase Inhibitor Asymmetric Dimethylarginine
homas Thum, MD,*§ Dimitrios Tsikas, PHD,† Sylvia Stein,* Maximilian Schultheiss,*
artin Eigenthaler, MD,‡ Stefan D. Anker, MD, PHD,§ Philip A. Poole-Wilson, MD, FRCP,§
eorg Ertl, MD,* Johann Bauersachs, MD*
ürzburg and Hannover, Germany; and London, United Kingdom
OBJECTIVES We tested the hypothesis that asymmetric dimethylarginine (ADMA) may be an endogenous
inhibitor of endothelial progenitor cells (EPCs).
BACKGROUND Endothelial progenitor cells play a pivotal role in regeneration of injured endothelium,
thereby limiting the formation of atherosclerotic lesions. Reduced numbers of EPCs may
affect progression of coronary artery disease. Regulation of EPC mobilization and function is
mediated in part by nitric oxide (NO). Endogenous inhibitors of NO synthases, such as
ADMA, contribute to endothelial dysfunction and injury.
METHODS We used flow cytometry and in vitro assays to investigate the relationship between EPC
number and function with ADMA plasma levels in patients with stable angina.
RESULTS The plasma concentration of ADMA was related to the severity of coronary artery disease and
correlated inversely with the number of circulating CD34/CD133 progenitor cells (r 
0.69; p  0.0001) and endothelial colony forming units (CFUs) (r  0.75; p  0.0001).
Adjusting for all patient characteristics, we confirmed these findings in multivariate regression
analyses. In vitro differentiation of EPCs was repressed by ADMA in a concentration-
dependent manner. Compared with untreated cells, ADMA reduced EPC incorporation into
endothelial tube-like structures to 27  11% (p  0.001). Asymmetric dimethylarginine
repressed the formation of CFUs from cultured peripheral blood mononuclear cells to 35 
7% (p  0.001). Asymmetric dimethylarginine decreased endothelial nitric oxide synthase
activity in EPCs to 64  6% (p  0.05) when compared with controls. Co-incubation with
the hydroxymethyl glutaryl coenzyme A reductase inhibitor rosuvastatin abolished the
detrimental effects of ADMA.
CONCLUSIONS Asymmetric dimethylarginine is an endogenous inhibitor of mobilization, differentiation, and
function of EPCs. This contributes to the cardiovascular risk in patients with high ADMA
levels and may explain low numbers and function of EPCs in patients with coronary artery
disease. (J Am Coll Cardiol 2005;46:1693–701) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.066Cardiology Foundation
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ifunctional and intact endothelium plays a crucial role in
he maintenance of vascular tone and structure. Endothelial
esions initiate atherosclerotic processes (1). Endothelial
See page 1702
rogenitor cells (EPCs) are mobilized from bone marrow
nto the circulation and contribute to replacement of dis-
ased endothelial cells, thereby limiting atherosclerotic
laque formation (2–4). Impaired mobilization of EPCs
rom bone marrow may lead to cardiovascular disease;
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ccepted April 27, 2005.ndeed, reduced numbers of circulating EPCs have been
ound in patients with coronary artery disease (CAD)
4–6). Moreover, patients with dysfunctional EPCs suffer
rom inadequate coronary collateral development (7). Bone
arrow-derived mononuclear cells from patients with CAD
ave reduced capacity to induce neovascularization (8). The
nderlying mechanism has not been determined.
Mobilization and differentiation of EPCs is known to be
odified by nitric oxide (NO) (9,10), and bone marrow-
xpressed endothelial NO synthase (eNOS) is essential for
he mobilization of stem and progenitor cells in vivo (9).
ndogenous NO synthase inhibitors, such as asymmetric
imethylarginine (ADMA), contribute to endothelial dys-
unction and inhibition of angiogenesis in vivo (11,12).
symmetric dimethylarginine is also a marker for cardio-
ascular risk and is correlated with the incidence of major
dverse cardiovascular events or deaths (13). Thus, NO
mpacts on important steps during differentiation of EPCs.
In a clinical study, we have investigated the relationship
etween plasma concentrations of ADMA and the number
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ADMA Inhibits Endothelial Progenitor Cells November 1, 2005:1693–701f circulating CD34/CD133 progenitor cells and endo-
helial colony forming units (CFUs) in patients with stable
ngina admitted for coronary angiography. The effects of
DMA on differentiation and functional capacity of cul-
ured EPCs from healthy donors were studied. The hypoth-
sis was that ADMA may be an important endogenous
nhibitor of EPC mobilization and function.
ETHODS
tudy subjects. Approval from the ethical committee of
he University of Würzburg was obtained, as was informed
ritten consent from patients. Eighty consecutive patients
dmitted to the hospital because of stable angina (49 men)
ged 39 to 81 years (mean age, 66.1  1.1 years) were
nrolled. All patients underwent cardiac catheterization,
nd CAD was excluded (CAD 0) or quantified by the
Abbreviations and Acronyms
ADMA  asymmetric dimethylarginine
CAD  coronary artery disease
CFU  colony forming unit
dil-ac-LDL  1,1=-dioctadecyl-3,3,3=,3-tetramethyl-
indocarbocyanine perchlorate labeled
acetylated low-density lipoprotein
eNOS  endothelial nitric oxide synthase
EPC  endothelial progenitor cell
FITC  fluorescein isothiocyanate
HMG-CoA  3-hydroxy-3-methyl-glutaryl coenzyme A
NO  nitric oxide
PBMC  peripheral blood mononuclear cells
able 1. Patient Characteristics
Control Subjects
(n  20)
CAD 1
(n  20)
ge (yrs) 64.6  1.8 63.7  1.0
ale (%) 55 60
D34/CD133 (%) 0.22  0.03 0.18  0.04
FU (number/well) 16.7  1.2 16.8  2.1
DMA (mol/l) 0.47  0.02 0.45  0.02
ypertension (%) 70 65
iabetes (%) 5 30
edication* (%)
Aspirin 75 90
Clopidogrel 15 25
ACE inhibitors/ARB 50 65
Beta-blocker 50 55
Statin 20 50
Nitrates 0 30
reatinine (mg/dl) 0.84  0.06 0.92  0.04
holesterol (mg/dl) 187.1  7.8 204.6  9.9
DL (mg/dl) 105.9  6.9 118.1  8.2
DL (mg/dl) 54.4  3.2 50.9  3.4
emoglobin (g/dl) 14.3  0.4 14.1  0.4
RP (mg/dl) 0.84  0.23 0.60  0.16
eukocytes (103/mm3) 6.9  0.4 7.0  0.4
alues are mean  standard error of the mean. *Medication at admission to hospita
ACE  angiotensin-converting enzyme; ADMA  asymmetric dimethylarginine; AR
umber of involved major coronary vessels; CFU  colony-forming units; CRP  C-reacumber of coronary arteries involved (CAD 1 to 3). For a
tenosis to qualify, the luminal diameter of the coronary
essel had to be reduced by 50%. Patient characteristics are
hown in Table 1.
easurement of ADMA in plasma samples. Blood
5 ml) was drawn from the antecubital vein of patients using
yringes containing ethylenediaminetetraacetic acid and im-
ediately put on ice. Blood samples were centrifuged at
,500 g and 4°C for 15 min. The plasma obtained was used
mmediately or stored at 80°C until further analysis.
ltrafiltrates (approximately 0.7 to 0.8 ml) from 1-ml
liquots of plasma samples were obtained by centrifugation
t 7,500 g and 20°C for 20 min using the Amicon Ultra
illipore ultrafiltration cartridges (Millipore, Schwalbach,
ermany). For detection and measurement of ADMA, a
as chromatography-tandem mass spectrometry method
as used (14). The measurements were performed on a
riple-stage quadruple mass spectrometer ThermoQuest
SQ 7000 (Finnigan MAT, San Jose, California) directly
nterfaced with a Trace 2000 series gas chromatograph
quipped with an autosampler AS 2000 (CE Instruments,
ustin, Texas). The gas chromatograph was equipped with
fused-silica capillary column Optima 17 (30 m 0.25 mm
D, 0.25 m film thickness) from Macherey-Nagel (Düren,
ermany). Synthetic ADMA served as the internal
tandard.
solation of peripheral blood mononuclear cells (PBMCs).
he PBMCs were isolated by Ficoll density centrifugation
s described (4). For in vitro assays, PBMCs were harvested
y blood withdrawal or leukapheresis (Cobe Spectra device,
ombro, Germany) of healthy volunteers (n  5).
D 2
 20)
CAD 3
(n  20)
All
(n  80)
p Value
CAD 0 vs. CAD 3
 2.0 69.5  3.0 66.1  1.1 0.11
65 65 61.3 0.75
 0.02 0.05  0.01 0.14  0.01 0.0001
 1.2 8.3  0.2 13.1  1.6 0.0001
 0.03 0.58  0.02 0.50  0.01 0.001
90 85 77.5  1.3 0.26
25 35 23.8  1.5 0.004
85 75 81.25 1.00
20 10 17.5 0.68
60 55 57.5 0.75
70 75 62.5 0.11
55 75 50 0.001
15 30 18.8 0.015
 0.06 0.98  0.06 0.93  0.03 0.08
 10.8 180.9  10.5 196.4  4.9 0.048†
 9.3 96.5  7.1 111.3  4.0 0.39
 3.5 48.6  3.7 51.4  1.7 0.24
 0.3 13.3  0.3 14.0  0.2 0.07
 0.10 0.83  0.20 0.70  0.09 0.97
 0.5 7.9  0.6 7.4  0.2 0.15
0.05 versus CAD 2.CA
(n
66.7
0.11
10.7
0.51
0.99
214.7
126.2
51.6
14.2
0.52
7.9
l. †p 
B  angiotensin-receptor blockers; CAD  coronary artery disease; CAD 0–3 
tive protein; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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November 1, 2005:1693–701 ADMA Inhibits Endothelial Progenitor Cellsetermination of progenitor cells. A variety of assays
ere used to determine the amount, differentiation, and
unction of EPCs as detailed in the subsequent text.
NDOTHELIAL PROGENITOR CELL CULTURE ASSAY. We
ultured 2  105 PBMCs on fibronectin-pre-coated eight-
ell chamber slides (Lab-Tek, Wiesbaden, Germany) in
ndothelial basal medium-2 (EBM2) culture medium sup-
lemented with EGM SingleQuots (Cambrex, Verviers,
elgium) for four days. To exclude contamination with
ature circulating endothelial cells, we carefully removed
ulture supernatant 8 h after initial seeding and placed it to
ew fibronectin-pre-coated chamber slides. After dilution
f 1,1=-dioctadecyl-3,3,3=,3-tetramethyl-indocarbocyanine
erchlorate labeled acetylated low-density lipoprotein
dil-ac-LDL) (Molecular Probes, Carlsbad, California) and
uorescein isothiocyanate (FITC)-conjugated lectin from
lex europeus (UEA-1; Sigma, Deisenhofen, Germany) in
erum-free EBM2 medium, cells were washed twice and
ncubated for 4 h at 37°C in EBM2 medium containing 10
g/ml dil-ac-LDL and 10 g/ml UEA-1. After washing,
ells were observed by fluorescence microscopy. Only
ouble-positive (dil-ac-LDL and UEA-1) cells were
ounted in at least eight independent randomly selected
igh-power fields.
ETECTION OF CD34/CD133 CELLS. The PBMCs were
solated by Ficoll density centrifugation as described previously
4). Thereafter, we incubated a volume of 60l (about 1 105
BMCs) with appropriate amounts of FITC-labeled mono-
lonal mouse antihuman CD34 and allophycocyanin-labeled
onoclonal mouse antihuman CD133/2 (293C3) antibody
Miltenyi Biotec, Bergisch Gladbach, Germany) for 10 min at
°C. In parallel experiments, we added appropriate isotype
ontrols (FITC-conjugated mouse immunoglobulin [Ig] G2a
onoclonal Ig and allophycocyanin-conjugated mouse IgG2b
onoclonal Ig). We acquired at least 20,000 cells using a
ACSCalibur cytometer (Becton Dickinson, Heidelberg,
ermany). The number of progenitor cells was expressed as a
ercentage of all PBMCs. Two investigators independently
ssessed the number of progenitor cells in blinded experiments.
FUS. The PBMCs were isolated by Ficoll density gradient
entrifugation, and 5  106 cells from leukapheresis donors
ere plated on fibronectin-coated six-well plates in En-
oCult medium (StemCell Technologies, St. Kathanimen,
ermany) according to the manufacturer’s instructions. In
ase of the patients study, 5 106 PBMCs were cultured on
bronectin-coated 12-well plates. After 48 h, non-adherent
ells were collected and plated in replicate fibronectin-
oated 24-well plates. Colonies were evaluated and quanti-
ed three days later. A colony was defined as a central core
f “round” cells with more elongated “sprouting” cells at the
eriphery and are referred to as early outgrowth CFU-
ndothelial cells (4). The endothelial lineage of these cells
as been confirmed previously by immunocytochemical ctaining for von Willebrand factor, vascular endothelial
rowth factor receptor 2, and CD31 (4).
NCORPORATION INTO TUBE-LIKE STRUCTURES. We mea-
ured incorporation of EPCs during endothelial tube for-
ation as described (15). Briefly, dil-ac-LDL pre-labeled
PCs (2 104 cells) were mixed with human umbilical vein
ndothelial cells (4  104) on an eight-well glass slide
re-coated with 200 l Matrigel (BD Bioscience, Heidel-
erg, Germany) in 500 l EBM-2 medium with supple-
ents (Cambrex) with the addition of 0, 1.0, 5.0, or 10.0
mol ADMA. Further, the 10-mol group was co-treated
ith rosuvastatin (10 mol). The concentration of rosuvas-
atin was based on a previous in vitro study (16). After eight
ours of incubation in a 5% CO2 humidified atmosphere at
7°C, cells were examined under a fluorescence microscope.
he amount of incorporated dil-ac-LDL-labeled EPCs in
ormed endothelial tubes was determined. Two investiga-
ors in blinded experiments examined eight randomly se-
ected high-power fields.
ETECTION OF eNOS ACTIVITY IN EPCs. Cultured EPCs
ere pretreated with 0, 1.0, 5.0, or 10.0 mol ADMA, as
ell as ADMA (10 mol)  rosuvastatin (10 mol) for
4 h. The EPCs were then incubated at 37°C with 5 mmol
-[guanidino-15N2]arginine for 8 h. Then, supernatant was
emoved and eNOS activity was determined by assessing the
onversion of L-[guanidino-15N2]arginine to
15N-nitrate
ith gas chromatography-mass spectrometry, according to a
reviously described method (17,18).
tatistical analysis. Data are expressed as mean values 
tandard error of the mean. A statistical analysis was
erformed by one-way analysis of variance followed by
ultiple comparisons using the Fisher protected least-
ignificant difference test. To analyze relationships between
ariables, simple, polynomial, and multivariate regression
nalyses were performed. Statistical analysis was performed
sing the StatView 5.0 statistic program (Abacus Concepts,
erkeley, California). Statistical significance was assumed at
 0.05.
ESULTS
linical study. We first investigated whether there was a
orrelation between the plasma concentration of ADMA
nd the number of circulating progenitor cells. Patients were
ivided into four groups: patients in whom coronary lesions
ere 50% of diameter (CAD 0) and patients with one,
wo, or three involved coronary vessels (CAD 1 to 3). There
as no statistical difference in age among the different
atient groups, as shown in Table 1. Total cholesterol levels
ere higher in CAD patients (CAD 0: 187.1  7.8 mg/dl
s. CAD 2: 214.7 10.8 mg/dl; p 0.05; Table 1), but not
orrelated with the severity of disease (Table 1) or the
mount of circulating CD133/CD34 progenitor cells
r  0.01). Circulating CD133/CD34 progenitor cells
orrelated well with endothelial CFU (r  0.83, p 
0
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ADMA Inhibits Endothelial Progenitor Cells November 1, 2005:1693–701.0001). The ADMA plasma concentrations in patients
ncreased with the severity of CAD (CAD 0: 0.47  0.02
mol/l vs. CAD 3: 0.58  0.02 mol/l; p  0.001) (Table
, Fig. 1A). There was an inverse correlation between
DMA plasma levels and the amount of CD133/CD34
rogenitor cells (r  0.69, p  0.0001) (Fig. 1B) or
ndothelial CFUs (r  0.75, p  0.0001) (Fig. 1D) in
solated PBMCs of patients, which were reduced by 77.3%
nd 50.3% in patients with three-vessel disease (CD133/
D34 cells: CAD 0: 0.22  0.03% vs. CAD 3: 0.05 
.01%, p 0.0001; CFU: CAD 0: 16.7 1.2 colonies/well
s. CAD 3: 8.3 0.7 colonies/well, p 0.0001) ( Table 1).
iabetes correlated with the number of vessels with CAD
p  0.004), whereas hypertension did not (Table 1).
atients with severe CAD were more commonly treated
ith a statin (p  0.001) or nitrates (p  0.05), whereas
reatment with other drugs was not different between the
roups (Table 1).
In stepwise multivariate regression analysis, we found
hat ADMA (standardized coefficient, 0.51; p  0.0001)
nd CAD (standardized coefficient, 0.43, p  0.01)
ndependently related to the number of circulating CD34/
D133 progenitor cells. In this analysis the following
actors were not significant predictors: age, plasma creati-
ine, leukocytes, hemoglobin, C-reactive protein, hyperten-
ion, diabetes mellitus, drug treatment (aspirin, clopidogrel,
ngiotensin-converting enzyme inhibitors, angiotensin re-
igure 1. Inverse correlation of plasma asymmetric dimethylarginine (AD
isease. The ADMA plasma levels (A) and circulating CD34/CD133
no coronary artery disease; CAD 1  one-vessel disease; CAD 2 
irculating CD34/CD133 progenitor cells or endothelial colony-formin
ith different severity of coronary artery disease (Table 1).eptor blockers, beta-blockers, statins, nitrates), total cho- desterol, low-density lipoprotein and high-density lipopro-
ein. In a similar analysis, we found that only ADMA
ignificantly predicted endothelial CFUs (standardized co-
fficient, 0.67, p  0.0001).
DMA inhibits differentiation and function of cultured
PCs. To test the hypothesis that ADMA may be an
ndogenous inhibitor of EPCs, we undertook further in
itro studies. ADMA reduced the amount of adherent
il-ac-LDL/UEA-1 double-positive cells after four days in
ulture to 37  4% (p  0.0001; n  5) (Fig. 2) in a
oncentration-dependent manner. The number of CFUs
ormed after five days of cell culture was repressed after
reatment with increasing concentrations of ADMA (Fig.
A). Co-treatment with the 3-hydroxy-3-methyl-glutaryl
oenzyme A (HMG-CoA) reductase inhibitor rosuvastatin
10 mol/l) normalized CFU numbers. We also assessed
he size of CFUs as a general proliferation marker of EPCs.
DMA treatment resulted in repression of the colony sizes
o 29  9% (p  0.0001; n  5), whereas rosuvastatin
ttenuated the anti-proliferative effects of ADMA (Fig.
B). Likewise, the capability to incorporate into tube-like
tructures in co-culture experiments with human umbilical
ein endothelial cells was repressed to 27  11% (p 
.001; n  5) of untreated cells after 24 h preincubation of
PCs with ADMA (10 mol/l). This inhibitory action was
eversed with rosuvastatin treatment (Fig. 4). Because the
unction of EPCs is, in part, regulated by NO, we also
) and CD34/CD133 progenitor cells in patients with coronary artery
nitor cells (B) in patients who underwent coronary angiography. CAD 0
vessel disease; CAD 3  three-vessel disease. (C) Correlation between
s (CFUs) (D) with the concentration of plasma ADMA levels in patientsMA
proge
two-etermined eNOS activity, which was reduced on ADMA
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November 1, 2005:1693–701 ADMA Inhibits Endothelial Progenitor Cellsreatment to 64  6% (p  0.05; n  5) of untreated cells
n culture supernatants, whereas co-treatment with rosu-
astatin completely normalized eNOS activity (Fig. 5).
ISCUSSION
n the present study, we show an inverse correlation
etween the number of circulating progenitor cells, the
everity of coronary heart disease, and ADMA plasma levels
n patients admitted to the hospital because of stable angina.
n vitro studies extend and support these clinical observa-
ions. ADMA markedly repressed EPC differentiation and
unction. Thus, the clinical findings were likely to be
ediated by reduced eNOS activity in ADMA-treated
PCs. eNOS-derived NO plays a key role in the process of
PC mobilization and differentiation (9,10) as well as
ngiogenesis (12). eNOS expression and activity in vitro and
n vivo is increased by statins (10,19,20). In the present
tudy, the HMG-CoA reductase inhibitor rosuvastatin
ormalized eNOS activity in ADMA-treated EPCs, and
eversed the inhibitory effects of ADMA on EPC differen-
iation and function.
In apolipoprotein E-deficient hypercholesterolemic mice,
igure 2. Inhibition of endothelial progenitor cells by asymmetric d
ndocarbocyanine perchlorate labeled acetylated low-density lipoprotein (d
ITC) double-positive cells after treatment of peripheral blood mononucle
rosuvastatin (RSV) (10 mol/l) for four days (each n  5). Cells were co
nvestigators.ncreased plasma ADMA levels and impaired angiogenesis cre closely correlated (12). When ADMA was directly
dded to a subcutaneously implanted disk angiogenesis
ystem, inhibition of basal and fibroblast growth factor-
nduced angiogenesis was observed in a dose-dependent
anner, showing that ADMA is an endogenous inhibitor
f angiogenesis (12). Recent findings have shown that
PCs play a pivotal role in neoangiogenesis (reviewed in
osordo and Dimmeler [21]) in keeping with our findings.
he ADMA-mediated impairment of EPCs may explain,
t least in part, reduced angiogenesis as observed by the
educed proliferation capacity of ADMA-treated CFUs in
his study. Neovascularization is impaired in diabetes, and
PCs from diabetic patients show decreased proliferation
apacity, adhesion, and incorporation into vascular struc-
ures (5). The close association between CAD and diabetes
22) as well as increased ADMA levels in this study cohort
ay suggest a contribution of ADMA-mediated reduction
f circulating EPCs and their function to CAD progression,
specially in diabetes. Interestingly, although total choles-
erol concentrations were higher in our cohort of CAD
atients, there was no significant correlation with the
everity of CAD or the amount of circulating progenitor
ylarginine (ADMA). Adherent 1,1=-dioctadecyl-3,3,3=,3-tetramethyl-
LDL)/fluorescein isothiocyanate labeled Ulex euroneus lectin-1 (UEA-1-
lls with increasing concentrations (1 to 10 mol) of ADMA and ADMA
in at least eight independent randomly selected high-power fields by twoimeth
il-ac-
ar ceells. Moreover, in multivariate regression analyses we could
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ADMA Inhibits Endothelial Progenitor Cells November 1, 2005:1693–701how that ADMA was the strongest predictor of circulating
rogenitor cells (both CD34/CD133 cells and endothe-
ial CFUs) independently of disease (diabetes), basic labo-
atory parameters, and treatment status, all of which have
reviously been shown to regulate EPCs (5,23–26). Al-
hough increasing age was previously reported to be corre-
ated with reduced EPC levels in patients with CAD (27),
his was not seen in our study, probably because of the
inimal variation of age among the patients.
Our study identifies enhanced ADMA concentrations in
atients with CAD as a predominant repressor of circulat-
ng progenitor cells in humans. The in vitro data further
upport a mechanistic link between increased ADMA levels
nd decreased EPCs, although we cannot completely rule
ut that this is, in part, explainable by co-correlation
ecause both ADMA and EPC levels are related to CAD.
The HMG-CoA reductase inhibitors are known to
ncrease EPC mobilization and function (10,28,29). Statin
reatment of patients with stable CAD for four weeks led to
three-fold increase in circulating progenitor cells (28).
his treatment also augmented the migratory capacity of
rogenitor cells. Some statins may also reduce ADMA
igure 3. Asymmetric dimethylarginine (ADMA) reduces the amount and
fter treatment of peripheral blood mononuclear cells with increasing conlasma concentrations. Recently, the effects of rosuvastatin vn plasma levels of ADMA in patients with hypercholes-
erolemia were investigated in a multicenter, randomized,
ouble-blind, placebo-controlled trial (30). Treatment for
ix weeks resulted in significant reductions of ADMA
lasma levels and increased flow-mediated vasodilation (30).
n contrast, treatment with either simvastatin or atorvastatin
id not reduce plasma ADMA levels, suggesting that the
DMA-lowering effect may be specific for rosuvastatin
31), although more and larger studies are needed for
onclusive evidence. In the present study, exposure to
osuvastatin normalized EPC differentiation and function.
ecause patients suffering from CAD have reduced num-
ers, colony-forming capacity, and migratory response of
PCs, rosuvastatin may be an interesting drug for both
uantitative and qualitative improvement of EPCs in pa-
ients with cardiovascular disease, as previously suggested
29). There may be ADMA-dependent and -independent
ffects of statins. In future studies it will be possible to
etermine which class of statins is superior in improving
PC mobilization, function, and ultimately cardiovascular
utcome.
We used a relatively high dose of rosuvastatin in our in
f colony-forming units. Amount (A) and size (B) of colony-forming units
tions of ADMA and ADMA  rosuvastatin (RSV) (each n  5).itro experiments. The concentration was based on mul-
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November 1, 2005:1693–701 ADMA Inhibits Endothelial Progenitor Cellsiple previous reports showing that in vitro, higher
oncentrations than in vivo are needed to show the
leiotropic effects of statins, especially when modulation
f eNOS activity is assessed (16,32,33). The concentra-
ions of ADMA used in vitro were higher than the
lasma levels of the patients. However, systemic ADMA
evels in general seem to be lower compared with con-
igure 4. Asymmetric dimethylarginine (ADMA) inhibits incorporation
PCs (labeled with 1,1=-dioctadecyl-3,3,3=,3-tetramethyl-indocarbocyanin
orming endothelial tubes from human umbilical vein endothelial cells (H
oncentrations of ADMA or ADMA  rosuvastatin (RSV) (each n  5
igh-power fields per experiment.
igure 5. Asymmetric dimethylarginine (ADMA) inhibits endothelial
itric oxide synthase (eNOS) activity in endothelial progenitor cells
EPCs). The eNOS activity was determined in EPC cell culture superna-
ants by assessing the conversion of L-[guanidino-15N2]arginine to
15N-s
itrate with gas chromatography/mass spectrometry. The 15N-nitrate/
4N-nitrate ratio is shown. RSV  rosuvastatin.entrations achieved in tissues (34). Therefore, the
DMA concentrations used in our in vitro assays are
ikely to reflect levels in local target tissues (34). We
ould show a significant positive correlation between
D34/CD133 cells and endothelial CFUs, which have
een shown to express von Willebrand factor, vascular endo-
helial growth factor receptor 2, and CD31 (4). ADMA
epressed both CD34/CD133 cells and endothelial CFUs,
hich supports the view that not only hematopoietic and
PCs but also other progenitor cell types may be inhibited by
igh ADMA plasma levels. This remains to be investigated in
he future.
In rats with heart failure after myocardial infarction, we
ave shown improvement of left ventricular remodeling and
ardiac function by statin treatment (35). The present study
uggests that improved EPC function by statins might
ontribute to this favorable effect. In patients with an acute
oronary syndrome, an intensive lipid-lowering statin regi-
en provides greater protection against death or major
ardiovascular events (36). In the present study more pa-
ients with the diagnosis of CAD were being treated with
othelial progenitor cells (EPCs) in tube-like structures. Incorporation of
chlorate labeled acetylated low-density lipoprotein [dil-ac-LDL]; red) in
Cs) (labeled with UEA1-FITC; green) after treatment with increasing
o investigators in blinded experiments examined eight randomly selectedof end
e per
UVEtatins at the time of admission to the hospital when
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lthough statins increase the number of circulating EPCs
10,28,29), this was not observed in our study cohort. There
re two possible reasons. First, dose-dependent effects of
tatin treatment regarding the amount of mobilized EPCs
re currently not known. Higher doses of certain statins
ight result in stronger improvement of EPC mobiliza-
ion and function. It is likely that if patients with severe
AD were not being treated with statins, EPC levels
ould be even lower. Second, the inhibitory effects of
DMA may be far stronger compared with statin effects,
nd thus the development of novel drugs that effectively
educe ADMA levels could lead to a novel therapeutic
oncept in the prevention and treatment of atherosclero-
is based on improved mobilization and function of
PCs.
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